DPx Holdings Sells Fine Chemicals Business

News
Article

PTSM: Pharmaceutical Technology Sourcing and Management

PTSM: Pharmaceutical Technology Sourcing and ManagementPTSM: Pharmaceutical Technology Sourcing and Management-08-05-2015
Volume 11
Issue 8

Investment group Ardian will acquire the fine chemicals business activities of DPx Holdings B.V.

Ardian, a private investment company, together with current management, announced on July 22 the acquisition of the Exclusive Synthesis (ES) and Maleic Anhydride Intermediates & Specialties (IM) business activities of DPx Holdings B.V., based in Linz, Austria. Details of the transaction were not disclosed.

ES develops and produces chemical intermediate products for agriculture and other industries. IM produces maleic anhydride, intermediates, derivatives, and esters. The groups had a combined sales of €200 million for the 2014 financial year and 390 employees.

With the support of Ardian, the management of ES and IM plans to significantly strengthen its market position, the company reports in a statement. Investment will focus on expanding the product portfolio through organic growth, strategic acquisitions, and expanding into new markets.

DPx Holdings B.V. is the parent company of the Patheon, DPx Fine Chemicals, and Banner Life Sciences businesses.

Source: DPx Holdings B.V.

 

Newsletter

Get the essential updates shaping the future of pharma manufacturing and compliance—subscribe today to Pharmaceutical Technology and never miss a breakthrough.

Recent Videos
Simona Guidi, Associate Director, ProPharma
Tore Bergsteiner
Behind the Headlines, Episode 20: CAR-T Milestones, Abbvie and Eli Lilly M&A Moves, and More
DC skyline at night with view of the White House and the Washington Monument | Image Credit: © Jessica - stock.adobe.com
Behind the Headlines, Episode 18
Related Content